Evidence map›Paper›PMID 38168105›Full record

ArticleChemistryOpen2024

CYTOP® 366: A Tertiary Phosphine Inaccessible by Most Traditional Hydrophosphination Methods.

Dino Amoroso, Jeff Dyck, Andrew Jackson, Michael Humeniuk, Eleanor Kendrick, Angelo Melaragni, Michael Moser, Izabela Wiater-Protas, Serguei Zavorine, Jade Markham

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ChemistryOpen, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Dino AmorosoPhosphorus Specialties, Technology Solutions, Syensqo, 9061 Garner Road, Niagara Falls, ON, L2H 0Y2, Canada.
Jeff DyckPhosphorus Specialties, Technology Solutions, Syensqo, 9061 Garner Road, Niagara Falls, ON, L2H 0Y2, Canada.
Andrew JacksonResearch and Innovation Technology Solutions, Syensqo, 1937 West Main Street, Stamford, CT 06902, USA.
Michael HumeniukPhosphorus Specialties, Technology Solutions, Syensqo, 9061 Garner Road, Niagara Falls, ON, L2H 0Y2, Canada.
Eleanor KendrickPhosphorus Specialties, Technology Solutions, Syensqo, Trinity Street, B69 4LN, Oldbury, UK.
Angelo MelaragniPhosphorus Specialties, Technology Solutions, Syensqo, 9061 Garner Road, Niagara Falls, ON, L2H 0Y2, Canada.
Michael MoserResearch and Innovation Technology Solutions, Syensqo, 1937 West Main Street, Stamford, CT 06902, USA.
Izabela Wiater-ProtasPhosphorus Specialties, Technology Solutions, Syensqo, 9061 Garner Road, Niagara Falls, ON, L2H 0Y2, Canada.
Serguei ZavorinePhosphorus Specialties, Technology Solutions, Syensqo, 9061 Garner Road, Niagara Falls, ON, L2H 0Y2, Canada.
Jade MarkhamPhosphorus Specialties, Technology Solutions, Syensqo, Trinity Street, B69 4LN, Oldbury, UK.ORCID https://orcid.org/0009-0009-1470-7369

Funding

Phosphorus Specialties and Technology Solutions
6 · The paper itself

Abstract

Homogenous catalysis is an essential tool within the commercial manufacture of bulk and fine chemicals. Within this, phosphine ligands, such as tricyclohexylphosphine, otherwise known as CYTOP® 366, are a crucial component. When designing a pathway to your ligand of choice, some key considerations include safety, yield and quality, but at commercial volumes we must also balance cost and consider the technologies readily available. Herein, we report the synthetic route that was chosen to manufacture tricyclohexylphosphine at commercial scale. We also consider, with the use of computational calculations, why traditional hydrophosphination methods failed, where the selected pathway succeeded.

Indexed as

CYTOP® 366HydrophosphinationMichael AdditionTertiary PhosphineTricyclohexylphosphine

Identifiers

PMID38168105
PMCPMC11164020

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.